Ennaid Therapeutics developing antiviral for COVID-19

Closely held Ennaid Therapeutics is advancing development of ENU200 as a therapeutic to treat the up to 80% of asymptomatic, mild-to-moderate cases of COVID-19 viral infections.

ENU200 is a repurposed, patent-pending, orally deliverable antiviral drug that was previously approved by the FDA for a different indication. In-silico modeling conducted by Ennaid has revealed that ENU200 delivers specific antiviral activity against two SARS-CoV-2 proteins: S glycoprotein and Mpro.

Ennaid’s science suggests that this simultaneous blockage may result in enhanced antiviral activity that could treat COVID-19 and other coronaviruses.

“Key to ENU200 is its target of two proteins on the SARS-CoV-2 virus that interfere with the virus’ ability to enter healthy cells and its replication,” Darnisha Harrison, founder and CEO, said in a statement, adding that ENU200 has the potential to be administered orally, enabling in-home treatment for COVID-19 infections.

Utilizing the FDA’s emergency/compassionate use regulatory pathway, or the FDA’s 505(b)(2) application process, Mr. Harrison said Ennaid believes it can quickly bring ENU200 to market by treating patients with COVID-19 in a Phase 3 in-home, self-dosing clinical trial of patients with asymptomatic, mild-to-moderate coronavirus infections, utilizing its iClickCare secure clinical reporting software service to monitor the in-home trials. If successful, he said ENU200 to be available to patients in six-to-nine months.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.